Last reviewed · How we verify

Ketamine + Lidocaine

State University of New York at Buffalo · Phase 3 active Small molecule

Ketamine blocks NMDA receptors while lidocaine provides local anesthetic effects, together modulating pain signaling and potentially enhancing anesthetic efficacy.

Ketamine blocks NMDA receptors while lidocaine provides local anesthetic effects, together modulating pain signaling and potentially enhancing anesthetic efficacy. Used for Anesthesia and analgesia (Phase 3 investigational).

At a glance

Generic nameKetamine + Lidocaine
SponsorState University of New York at Buffalo
Drug classNMDA receptor antagonist + local anesthetic combination
TargetNMDA receptor; voltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia; Pain Management
PhasePhase 3

Mechanism of action

Ketamine is a non-competitive NMDA receptor antagonist that produces dissociative anesthesia and analgesia by blocking excitatory glutamatergic neurotransmission. Lidocaine is a local anesthetic that blocks sodium channels, inhibiting nerve conduction. The combination may provide synergistic analgesic and anesthetic effects with potentially reduced side effects compared to either agent alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: